AZ's Farxiga meets in Phase III for Type II diabetes with moderate renal impairment

In March, AstraZeneca plc (LSE:AZN; NYSE:AZN) reported data from the double-blind, international Phase III DERIVE trial in 321 Type

Read the full 196 word article

User Sign In